Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
6 participants
INTERVENTIONAL
2013-04-30
2016-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
NCT01381016
Prevention of Obesity in Women Via Estradiol Regulation
NCT00687739
Resting Energy Expenditure in Postmenopausal Women
NCT06905886
The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome
NCT03396978
Timing Estrogen After MenoPaUSe
NCT01605071
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Estrogen suppression
Estrogen production will be suppressed using Lupron, a drug that blocks normal production of ovarian hormones
Estrogen suppression
Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Estrogen suppression
Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Normal menstrual cycles
* Premenopausal
Exclusion Criteria
* on hormonal contraceptive or menopausal therapy
* positive pregnancy test
* intention to become pregnant or start hormonal contraceptive therapy during the period of study
* lactation
* severe osteopenia or osteoporosis (i.e., proximal femur or lumbar spine t scores \< -2.0)
* abnormal vaginal bleeding
* thyroid dysfunction
* uncontrolled hypertension
* exercising at least 30 minutes per day at a moderate to vigorous intensity \>1 d/wk) over the past 6 months
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward Melanson, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-0149
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.